News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
PIPELINE
[Updated] Pharma Licensing Deals Involving Chinese Companies in 2023
In 2023, the Chinese pharma industry witnessed a total of 124 licensing deals, with a combined transaction value of USD 50.59 billion. Compared to the previous year, the transaction value of licensing deals in 2023 increased by 41% year on year, while the number of deals decreased by 38%.
Apr 29, 2024
PIPELINE
Chinese Antibody-drug Conjugates (ADCs) Licensed Overseas Exceeds $23 Billion This Year
On Dec 20, 2023, Hansoh Pharma, a Chinese biopharma company, announced that it had reached an exclusive deal with GSK for HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3. This deal is one of 15 cross-border licensing deals inked this year between Chinese ADC-focused companies and multinational corporations this year.
Dec 21, 2023
PIPELINE
Licensing Deals Involving Chinese Pharma Companies in H1 2022
In H1 2022, China's pharma companies have taken part in multiple licensing deals. The in-licensing deals, in which Chinese companies are licensees, highlight AI-assisted drug R&D and COVID-19 vaccines/drugs.The out-licensing deals, in which Chinese companies were licensors, are mostly in the field of oncology.
Jul 14, 2022
PIPELINE
Are Cross-Border Licensing Deals a Shortcut to China's Pharma Market?
In 2021 H1, China has made 50 in-licensing deals, among which the top 10 add up to $5,197.5 million in value. Licensing deals do have advantages for promoting foreign drugs in China, but they are not shortcuts. Prudent work still needs to be done before making the deals.
Dec 07, 2021
